Psychological support provided by GPs is an important factor for the maintenance of a positive sense of wellbeing for patients with persistent pain.
Regular assessment and monitoring of non-motor symptoms enable the clinician to support the implementation of effective interventions.
Many patients affected by the COVID-19-related temporary suspension of non-urgent elective surgery will present to their general practitioners for symptom management in the interim period.
This article outlines the key principles for assessment and treatment of De Quervain’s tenosynovitis to enable early diagnosis and successful treatment outcomes.
Faecal incontinence in residential aged care is highly prevalent, distressing and difficult to treat, and the evidence base for treatment remains deficient.
Chronic non-cancer pain management illustrates the case for reconceptualising chronic condition management using a generic lifestyle-based approach.
The majority of referrals to a regional outpatient nephrology service contained insufficient detail to meet Australian guidelines.
This article aims to provide evidence-based information to GPs, aiding the decision to initiate sodium–glucose cotransporter 2 (SGLT2) inhibitors for chronic kidney disease patients.
This article investigates the prevalence of chronic pain in a rural setting and the use of specialist pain clinics and examines factors associated with well-managed pain.
These presentations provide fertile ground for educating patients about infections, self-management options, dealing with uncertainty and responsible use of medicines.
Challenges that multiple sclerosis presents include early detection, awareness of new therapies, work with multidisciplinary teams and its long-term management as a chronic disease.
Medication cessation or dose reduction may be required for patients with chronic kidney disease to prevent medication accumulation, adverse medication events and kidney injury.
Patients with advanced age, significant comorbidities and poor functional status may not gain a survival benefit with dialysis when compared with being managed conservatively.
Buprenorphine–naloxone is well tolerated by patients with chronic pain, and has the potential to improve pain scores and affective symptoms.